Text Size
55 studies found for:    "Kidney Diseases, Cystic"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource
Conditions: Hepato/Renal Fibrocystic Disease;   Autosomal Recessive Polycystic Kidney Disease;   Joubert Syndrome;   Bardet Biedl Syndrome;   Meckel-Gruber Syndrome;   Congenital Hepatic Fibrosis;   Caroli Syndrome;   Oro-Facial-Digital Syndrome Type I;   Nephronophthisis;   Glomerulocystic Kidney Disease
Intervention:
2 Unknown † UAB Recessive PKD Research and Translational Core Center
Condition: Autosomal Recessive Polycystic Kidney Disease
Intervention:
3 Completed Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Polycystic Kidney, Autosomal Dominant
Interventions: Drug: pravastatin;   Drug: Placebo
4 Not yet recruiting Contrast-enhanced Ultrasound for the Evaluation of Complex Renal Cysts
Condition: Complex Renal Cyst
Intervention: Procedure: Contrast-enhanced ultrasound
5 Recruiting Clinical and Molecular Investigations Into Ciliopathies
Conditions: Autosomal Recessive Polycystic Kidney Disease;   Congenital Hepatic Fibrosis;   Caroli's Disease;   Polycystic Kidney Disease;   Joubert Syndrome;   Cerebro-Oculo-Renal Syndromes;   COACH Syndrome;   Senior-Loken Syndrome;   Dekaban-Arima Syndrome;   Cogan Oculomotor Apraxia;   Nephronophthisis;   Bardet-Biedl Syndrome;   Alstrom Syndrome;   Oral-Facial-Digital Syndrome
Intervention:
6 Completed Assessment of the Prevalence of Genes AHI1, NPHP1 and CEP290 in Joubert Syndrome
Conditions: Joubert Syndrome;   Cerebello-oculo-renal Syndromes
Intervention: Biological: Whole blood sample
7 Active, not recruiting Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
Condition: Polycystic Liver Disease
Intervention: Drug: Lanreotide
8 Terminated The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease
Condition: Polycystic Kidney, Autosomal Dominant
Intervention:
9 Completed The Vienna RAP Pilot Study
Condition: ADPKD
Intervention: Drug: Sirolimus
10 Completed The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease
Condition: Polycystic Kidney, Autosomal Dominant
Interventions: Behavioral: High Sodium Diet;   Behavioral: Low Sodium Diet
11 Active, not recruiting Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study
Condition: Kidney, Polycystic, Autosomal Dominant
Intervention: Procedure: video thorascopic splanchnicectomy (VSPL)
12 Unknown † Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Drug: Rapamycin
13 Recruiting Pasireotide LAR in Severe Polycystic Liver Disease
Conditions: Somatostatin Analogs;   Polycystic Liver Disease;   Autosomal Dominant Polycystic Kidney Disease;   Autosomal Dominant Polycystic Liver Disease
Interventions: Drug: Pasireotide LAR;   Drug: Placebo
14 Recruiting A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Other: ADPKD Diet
15 Completed Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety
Condition: Polycystic Kidney
Interventions: Drug: Sirolimus;   Drug: conventional therapy
16 Unknown † Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Drug: Sirolimus;   Other: Standard
17 Enrolling by invitation Open-Label Tolvaptan Study in Subjects With ADPKD
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention: Drug: Tolvaptan
18 Active, not recruiting A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
Condition: Autosomal Dominant Polycystic Kidney Disease （ADPKD)
Intervention: Drug: tolvaptan
19 Active, not recruiting A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Drug: OPC-41061
20 Recruiting 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Tolvaptan MR;   Drug: Tolvaptan IR;   Drug: Placebo
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years